Drug Trial Radar · NCT07682506
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
405
Planned (sponsor's estimate)
Start
Aug 4, 2026
Primary completion
Feb 23, 2028
Study completion Oct 4, 2028
Sponsor
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.
Conditions
- Vitiligo
Interventions
MH004 1.0% OintmentDrug
MH004 1% ointment applied topically to the affected area as a thin film twice a day (BID).
MH004 Placebo OintmentDrug
MH004 Placebo ointment applied topically to the affected area as a thin film twice a day (BID).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving at least a 75% improvement from baseline in Facial Vitiligo Area Scoring Index (F-VASI75) at Week 24 (W24)Time frame: Baseline; Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.